Is Orion Oyj (HLSE:ORNBV) Undervalued Following Strong Earnings And Higher 2026 Guidance?
Orion Oyj earnings jump and guidance raised for 2026
Orion Oyj (HLSE:ORNBV) drew fresh attention after reporting higher second quarter 2026 sales and net income, alongside an updated full year outlook that now points to increased net sales and operating profit ranges.
The company reported second quarter 2026 sales of €521.6 million compared with €416.5 million a year earlier. Net income was €140.2 million versus €82.5 million, with basic and diluted earnings per share from continuing operations at €1 compared with €0.59.
See our latest analysis for Orion Oyj.
Orion Oyj's latest earnings and guidance update arrives after a strong run in the stock, with a 30 day share price return of 15.36% and a 90 day share price return of 22.35%. The 3 year total shareholder return of 150.47% and 5 year total shareholder return of 161.97% point to longer term momentum that recent results appear to have reinforced.
If this kind of sustained performance has your attention, it can be helpful to widen your watchlist using a focused screener such as 106 top founder-led companies
The recent jump in Orion Oyj’s share price sits opposite a wide gap between the current market price and some valuation estimates. So where does fair value really lie as the stock trades above the average analyst target?
Most Popular Narrative: 8.6% Overvalued
Analysts following Orion Oyj see fair value at €74.33 compared with the latest close at €80.75. This view places more weight on projected cash flows and margins than on today’s share price strength.
A clear shift of the clinical pipeline toward oncology, including opevesostat Phase III OMAHA studies with survival focused endpoints and the planned Phase II program for TEAD inhibitor ODM-212, places Orion in areas of sustained demand for cancer treatments. This can influence long term revenue mix and earnings potential.
This oncology tilt is incorporated into assumptions on margins, adjusted growth rates and a lower future P/E in the fair value analysis. The full narrative explains how these factors connect to the €74.33 figure without relying on extreme scenarios.
Result: Fair Value of €74.33 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Orion Oyj’s oncology pipeline and the €180 million Nubeqa milestone could still shift expectations if trial results or milestone timing differ from current assumptions.
Find out about the key risks to this Orion Oyj narrative.
Another View On Orion Oyj's Valuation
The analyst narrative suggests Orion Oyj is 8.6% overvalued at €80.75 relative to a €74.33 fair value. Our DCF model presents a different perspective. On that view, the stock trades at €80.75 compared with an estimated future cash flow value of €156.79, which indicates it may be undervalued.
This gap between analyst targets and the SWS DCF model raises a simple question for investors: Which assumptions feel more realistic for Orion Oyj over the next few years, and how much weight should each method receive in your own analysis?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Orion Oyj for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 250 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With Orion Oyj presenting mixed valuation signals and growing optimism around its rewards, it makes sense to review the numbers directly and move quickly to shape your own view. To see what sits behind that optimism, take a closer look at the 3 key rewards
Looking for more Orion Oyj style investment ideas?
If Orion Oyj has sharpened your focus, now is a good time to broaden your watchlist with other stocks that match clear, data driven criteria.
- Target dependable income opportunities by reviewing 441 dividend fortresses that may suit a portfolio focused on steady payouts.
- Spot potential mispricings early by scanning screener containing 511 high quality undiscovered gems that the wider market might not be watching yet.
- Prioritise resilience in tougher periods by checking 302 resilient stocks with low risk scores that score well on downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com